Vitiligo onset following anti-inflammatory biological therapy: a scoping review. (PubMed, Front Immunol) - Oct 24, 2026 - "Tumor necrosis factor-alpha (TNFα) inhibitors (infliximab, adalimumab, certolizumab pegol) were the most frequent suspected drugs (>50% of patients), followed by anti-IL-17A (ixekizumab, secukinumab) and anti-IL-12/23 (ustekinumab). Four cases were linked to anti-IL-4/13 (dupilumab)...While de novo vitiligo is reported as a potential adverse event of biological therapies, evidence for a direct causal relationship remains weak, with cases involving non-anti-TNFα agents appearing anecdotal. The co-occurrence of underlying autoimmune comorbidities in these patients points towards a coincidental rather than a causal relationship, highlighting the need for further research to fully elucidate this association."
Journal • Review • Dermatology • Immunology • Oncology • Vitiligo • IL12A • IL17A • IL4
|
|
Angelo Valerio Marzano; Chiara Moltrasio; Gianluca Tavoletti; Luisa Carlotta Rossi; Maurizio Romagnuolo; Silvia Alberti Violetti
|